DeCure for Brachycephaly, trichomegaly, and developmental delay
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for brachycephaly, trichomegaly, and developmental delay — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleBrachycephaly, trichomegaly, and developmental delay maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for brachycephaly, trichomegaly, and developmental delay is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
A 1997 case report describes a boy with Dubowitz syndrome, an autosomal recessive condition that includes pre- and postnatal growth retardation, eczema, telecanthus, epicanthal folds, blepharophimosis, ptosis, and broadening of the bridge and tip of the nose. The authors note that the initial patients described had varying degrees of mental retardation, but this boy did not have developmental delays, providing evidence that the phenotype includes normal neurodevelopmental status. No drug treatment is mentioned in this abstract.
A 2007 study of 110 live-born preterm infants with gestational age under 27 weeks reported 52% mortality. Among the 53 surviving infants, 48 (91%) had regular follow-up. At 2 years corrected age, 90% had normal neurology, 4% had nonambulant cerebral palsy, 2% had ambulant cerebral palsy, and 4% had mild neurologic signs. Developmental outcome at 2 years showed 40% had a developmental quotient above -1 standard deviation, 6% had mild delay (DQ between -1 and -2 SD), 35% had moderate delay (DQ between -2 and -3 SD), and 19% had severe delay (DQ below -3 SD). Overall disability was found in 64%, severe disability in 27%. Profound growth failure in weight and head circumference below the 3rd centile at 2 years was recorded in 39% and 19% respectively. The authors concluded that developmental delay is very common in these preterm infants and exceeds the number of neurological disabilities including cerebral palsy. No drug treatment is mentioned in this abstract.
A 2017 review of investigational drugs for Fragile X syndrome, the most common inherited cause of intellectual disability, examined preclinical, Phase I, and Phase II trials of agents targeting the metabotropic glutamate receptor system, GABAergic agents, and miscellaneous modulators. The review states that initial trials failed to demonstrate sufficient significance, and that differences in outcome between animal models and humans highlighted unique challenges in carrying out trials in cognitively and behaviorally challenged individuals, as well as a dearth of clinically relevant outcome measures. No specific drug is named in this abstract, and no positive efficacy data are reported.
What is still missing for the combination of brachycephaly, trichomegaly, and developmental delay is any clinical trial data, any identified drug, any funding for a trial, any patient stratification, and any validated outcome measures specific to this phenotype.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Klinische Pädiatrie · 2007 · 32 citations
Neurodevelopmental Outcome at 2 Years in 23 to 26 Weeks Old Gestation Infants
AbstractBACKGROUND: Assessment of neurologic and developmental outcome at 2 years age of infants with gestational age (GA)<27 weeks, born between 1996-2001. PATIENTS: A total of 110 live-born preterm infants with GA<27 weeks. METHODS: Main outcome criterions: Neurologic examination (according to Touwen) and classification of cerebral palsy by using the Gross Motor Function Classification System (GMFCS) at the corrected age of 1 and 2 years; assessment of mental and psychomotor development by using the Griffith Mental Development scales at the corrected age of 2 years; growth assessment at birth, 1 and 2 years. RESULTS: Mortality was 52%. Regular follow up was performed in 48 (91%) of the 53 surviving infants. Neurologic outcome: at 1 year age: 2% nonambulant cerebral palsy, 25% mild neurologic signs and 73% normal; at 2 years age: 4% nonambulant cerebral palsy, 2% ambulant cerebral palsy, 4% mild neurologic signs and 90% normal neurology. Developmental outcome at 2 years age: 40% DQ>-1 SD, 6% DQ between -1 SD and -2 SD (mild delay), 35% DQ between -2 SD and -3 SD (moderate delay) and 19% DQ<-3 SD (severe delay). Overall disability was found in 64%, severe disability in 27% of the infants. Profound growth failure in weight and head circumference<3rd centile at 2 years age was recorded in 39 and 19% of the infants, respectively. CONCLUSION: Developmental delay is very common in preterm infants<27 GA and exceeds the number of neurological disabilities (including cerebral palsy).
Journal of Child and Adolescent Psychopharmacology · 2017 · 5 citations
Review of Salient Investigational Drugs for the Treatment of Fragile X Syndrome
AbstractOBJECTIVES: Fragile X syndrome (FXS) is the most common inherited cause of intellectual disability, in addition to being the commonest diagnosable cause of autism. The identification of the biochemical mechanism underlying this disorder has provided amenable targets for therapy. This review aims to provide an overview of investigational drug therapies for FXS. METHODS: The authors carried out a search of clinical and preclinical trials for FXS in PubMed and on the U.S. National Institutes of Health index of clinical trials ( www.clinicaltrials.gov ). We limited our review to Phase II trials or more preliminary and reviewed the associated publications for these studies, complemented by a review of the literature on PubMed. RESULTS: The review of the preclinical, Phase I, and Phase II trials of agents with therapeutic potential in FXS revolves around an understanding of the putative pathways in the pathogenesis of FXS. While there is significant overlap between some of these pathways, the agents can be categorized as modulators of the metabotropic glutamate receptor system, GABAergic agents, and miscellaneous modulators affecting other pathways. CONCLUSION: As trials involving agents targeting different aspects of the molecular biology proceed, common themes have emerged. With the great hope came great disappointment as the initial trials failed to demonstrate sufficient significance. In particular, the differences in outcome between the animal models and humans have highlighted the unique challenges of carrying out trials in these cognitively and behaviorally challenged individuals, as well as a dearth of clinically relevant outcome measures for use in medication trials. However, in reviewing and reframing the studies of the last decade, many important lessons have been learned, which will ultimately have a greater impact on therapeutic research in the field of developmental delay as a whole.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
